Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline

Fineline Cube Apr 30, 2026
Company Deals

Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China

Fineline Cube Apr 30, 2026
Company Deals

Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets

Fineline Cube Apr 29, 2026
Company Deals

Hengrui Pharmaceuticals Partners with Sun Yat-sen University to Integrate Industry-Academia Innovation Ecosystem

Fineline Cube Apr 29, 2026
Company Deals

Vivacta Biotechnology Secures $50M+ Series A Financing to Advance In Vivo CAR-T Therapy GT801

Fineline Cube Apr 29, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Lianhuan Pharmaceutical’s SGLT-2 Inhibitor LH-1801 Meets Primary Endpoint in Phase III Type 2 Diabetes Trial

Fineline Cube Apr 30, 2026
Company Drug

Allist Pharmaceuticals Secures NMPA Approval for Pivotal Trial of Furmonertinib Against Standard EGFR TKIs in Rare NSCLC Mutations

Fineline Cube Apr 30, 2026
Company Deals

I‑Mab Announces Global Transformation, NovaBridge Rebranding, and $37 M Acquisition of VIS‑101

Fineline Cube Oct 17, 2025

I‑MAB Biopharma (NASDAQ: IMAB), a public company under the CBC Group, today revealed a strategic...

Company Drug

CStone’s Sugemalimab Receives Positive EMA Opinion for Stage III NSCLC

Fineline Cube Oct 17, 2025

CStone Pharmaceuticals (HKG: 2616) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal...

Company Deals

Viatris Acquires Aculys Pharma to Secure Japanese Rights for Pitolisant and Spydia

Fineline Cube Oct 17, 2025

Viatris Inc. (NASDAQ: VTRS) today announced the completion of its acquisition of Aculys Pharma, gaining...

Company Deals

Gan & Lee Pharma, Fiocruz Sign MoU to Advance GZR4 and GZR102 Insulin Candidates

Fineline Cube Oct 17, 2025

Gan & Lee Pharmaceuticals (SHA: 603087) announced today that it has signed a Memorandum of...

Company Deals

Hansoh Pharma Grants Roche Exclusive Global Rights to CDH17‑Targeting ADC HS‑20110

Fineline Cube Oct 17, 2025

Hansoh Pharmaceutical Group (HKG: 3692) today announced a licensing agreement with Roche (SWX: ROG, OTCMKTS:...

Company Drug

Shanghai Junshi Biosciences Secures FDA Approval for JS207 Phase II/III Trial

Fineline Cube Oct 17, 2025

Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) today announced that the U.S. Food...

Company

AstraZeneca China Integrates Symbicort and Breztri Sales Teams in New Organizational Shake‑Up

Fineline Cube Oct 17, 2025

AstraZeneca (AZ; NASDAQ: AZN) announced a strategic re‑alignment of its respiratory inhalation portfolio in China, consolidating...

Company Deals

Leads Biolabs, Dianthus Therapeutics Announce Global Partnership for LBL‑047 Bispecific Fusion Protein

Fineline Cube Oct 17, 2025

Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) today announced an exclusive global partnership with Dianthus Therapeutics...

Company Deals

NeuroGen Pharma Secures Exclusive Rights to Brexpiprazole Orally Disintegrating Film from Bocimed

Fineline Cube Oct 16, 2025

China‑based NeuroGen Pharma and Bocimed announced today that they have entered into an exclusive product‑transfer...

Company Drug

Chia Tai Tianqing Secures NMPA Approval for Phase III Trial of TQB2868 + Anlotinib in First‑Line mPDAC Therapy

Fineline Cube Oct 16, 2025

Chia Tai Tianqing, a wholly‑owned subsidiary of Sino Biopharmaceutical (HKG: 1177), announced today that the...

Company Drug

Lepu Biopharma Enrolls First Patient in Phase II Trial of MRG006A, the World’s First GPC3‑Targeting ADC

Fineline Cube Oct 16, 2025

Lepu Biopharma Co., Ltd. (HKG: 2157) announced today that it has successfully enrolled the first...

Company Deals

Jacobio Pharmaceuticals Secures 80% Equity Investment in Jacoray from Oceanpine Capital

Fineline Cube Oct 16, 2025

Jacobio Pharmaceuticals (HKG: 1167) today announced a capital‑increase and equity‑transfer agreement that will see Shanxi...

Policy / Regulatory

Zhejiang Authority Imposes Administrative Penalties on Dahongying Pharma for Substandard Fluorouracil Injection

Fineline Cube Oct 16, 2025

The Zhejiang Provincial Medical Products Administration announced that Ningbo Dahongying Pharmaceutical Co., Ltd. has been...

Company Drug

HELP Therapeutics Secures NMPA Approval for HiCM388, China’s First Cell‑Based Therapy for STEMI

Fineline Cube Oct 16, 2025

HELP Therapeutics Corp., a pioneer in cell‑based therapeutics, announced that the National Medical Products Administration...

Company

Abbott Reports Q3 2025 Revenue of $11.369 B, Up 6.9% YoY – Strong Growth Across Nutrition & Devices Segments

Fineline Cube Oct 16, 2025

Abbott Laboratories (NYSE: ABT) today released its financial results for the quarter ended September 30, 2025. For...

Company Deals

Haihe Biopharma Grants Taiho Pharmaceutical Exclusive License for Risovalisib in Japan

Fineline Cube Oct 16, 2025

China‑based Haihe Biopharma Co., Ltd. (the “Licensor”) announced today that it has entered into an...

Company Deals

Genesis Healthcare & MGI Sign Strategic MOU to Accelerate Precision Medicine in Japan

Fineline Cube Oct 16, 2025

Genesis Healthcare, a leading Japanese genetic‑testing provider, today announced the signing of a Memorandum of...

Company Deals

Nuance Pharma Partners with Stallergenes Greer to Launch Actair in China

Fineline Cube Oct 15, 2025

Nuance Pharma, an innovation-focused biopharmaceutical company, and Stallergenes Greer, a global leader in the allergy...

Policy / Regulatory

Pfizer CEO Bourla Highlights Benefits of China Biotech Collaborations at NY Gala

Fineline Cube Oct 15, 2025

Albert Bourla, CEO of Pfizer Inc. (NYSE: PFE), highlighted the benefits of collaborations between multinational...

Company Deals

Uni-Bio Science Partners with Sinovac to Expand Teriparatide Injection Globally

Fineline Cube Oct 15, 2025

Uni-Bio Science Group Limited (HKG: 0690), a China-based company, announced on September 12, 2025, that...

Posts pagination

1 … 86 87 88 … 659

Recent updates

  • AbbVie Reports 12.4% Revenue Growth in Q1 2026 Driven by Immunology and Neuroscience Strength
  • 3SBio Reports 94% Revenue Surge to $2.58B in 2025 Driven by $6B Pfizer PD-1/VEGF Bispecific Antibody Deal
  • Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline
  • Lianhuan Pharmaceutical’s SGLT-2 Inhibitor LH-1801 Meets Primary Endpoint in Phase III Type 2 Diabetes Trial
  • Allist Pharmaceuticals Secures NMPA Approval for Pivotal Trial of Furmonertinib Against Standard EGFR TKIs in Rare NSCLC Mutations
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

AbbVie Reports 12.4% Revenue Growth in Q1 2026 Driven by Immunology and Neuroscience Strength

Company

3SBio Reports 94% Revenue Surge to $2.58B in 2025 Driven by $6B Pfizer PD-1/VEGF Bispecific Antibody Deal

Company Deals

Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline

Company Drug

Lianhuan Pharmaceutical’s SGLT-2 Inhibitor LH-1801 Meets Primary Endpoint in Phase III Type 2 Diabetes Trial

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.